Publikationen

2024

Goette A et al. Atrial Cardiomyopathy Revisited - Evolution of a Concept. A Clinical Consensus Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Association (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace 30 July 2024. doi: 10.1093/europace/euae204

2022-2023

Toennis T et al. The influence of atrial high rate episodes on stroke and cardiovascular death – an update. Europace 22 June 2023. doi: 10.1093/europace/euad166

Ladwig KH et al. Covid‑19 pandemic induced traumatizing medical job contents and mental health distortions of physicians working in private practices and in hospitals. Nature Scientific Reports. 2023; 13:5284. DOI: 10.1038/s41598-023-32412-y

Jensen M, Suling A, Metzner A, Schnabel R, Borof K, Goette A, Haeusler KG, Zapf A, Wegscheider K, Fabritz L, Diener H-C, Thomalla G, Kirchhof P. Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST- AFNET 4 trial. Lancet Neurol 2023; 22: 45–54. DOI: 10.1016/PIIS1474-4422(22)00436-7

Goette A, Lip GYH, Gorenek B. What acute cardiac care physicians need to know from the latest 2022 ESC Guidelines for ventricular tachycardia and sudden cardiac death. European Heart Journal: Acute Cardiovascular Care (2022) 00, 1–7. DOI: 10.1093/ehjacc/zuac149

Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff H, Gerss J, Haeusler KG, Hewing B, Hoyer J, Juergensmeyer S, Klingenheben T, Knapp G, Rump LC, Schmidt-Guertler H, Wanner C, Kirchhof P, Goerlich D. 2022. A randomized controlled trial comparing apixaban to the vitamin Kantagonist phenprocoumon in patients on chronic hemodialysis – the AXADIA – AFNET 8 study. Circulation 06.11.2022. doi: 10.1161/CIRCULATIONAHA.122.062779

Fabritz L, Connolly D, Czarnecki E, Dudek D, Guasch E, Haase D, Huebner T, Zlahoda-Huzior A, Jolly K, Kirchhof P, Schotten U, Obergassel J, Schotten, U, Vettorazzi E, Winkelmann SJ, Zapf A, Schnabel R. Smartphone and wearable detected atrial arrhythmias in Older Adults: Results of a fully digital European Case finding study European Heart Journal - Digital Health, 2022 November 01. doi:10.1093/ehjdh/ztac067

Goette A. Is Periodontitis a Modifiable Risk Factor for Atrial Fibrillation Substrate? JACC: Clinical Electrophysiology, 2022 Oktober 31. doi:10.1016/j.jacep.2022.09.013

Goette A, Brandner S. Vorhofflimmern auf der Intensivstation Springer Medizin Verlag, 2022 September 2. doi:10.1007/s00399-022-00899-z

Eckardt L, Sehner S, Suling A, Borof K, Breithardt G, Crijns HJG, Goette A, Wegscheider K, Zapf A, Metzner A, Kirchhof P. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST – AFNET 4 trial. European Heart Journal, 29 August 2022. doi: 10.1093/eurheartj/ehac471

Zeemering S, Isaacs A, Winters J, Maesen B, Bidar E, Dimopoulou C, Guasch E, Batlle M, Haase D, Hatem S, Kara M, Kääb S, Mont L, Sinner M, Wakili R, Maessen J, Crijns HJGM, Fabritz L, Kirchhof P. Stoll M, Schotten S. Atrial fibrillation in the presence and absence of heart failure enhances expression of genes involved in cardomyocyte structure, conduction properties, fibrosis, inflammation, and endothelial dysfunction. HeartRhythm Journal, 21 August 2022. doi: 10.1016/j.hrthm.2022.08.019

Rillig A, Borof K, Breithardt G, Camm AJ, Crijns HJGM, Goette A, Kuck KH, Metzner A, Vardas P, Vettorazzi E, Wegscheider K, Zapf A, Kirchhof P. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation 2022. Epub 15 August 2022. doi: 10.1161/CIRCULATIONAHA.122.060274

Schnabel RB, Goette A, Schotten U, Willems S, Kirchhof P, et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. EP Europace, 27 July 2022. euac062. doi: 10.1093/europace/euac062

Goette A, Borof K, Breithardt G, Camm AJ, Crijns HJG, Kuck KH, Wegscheider K, Kirchhof P. Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. J Am Coll Cardiol. 2022;80(4):283-295 

Fabritz L, Connolly D, Czarnecki E, Dudek D, Zlahoda-Huzior A, Guasch E, Haase D, Huebner T, Jolly K, Kirchhof P, Schotten U, Zapf A, Schnabel R. Remote Design of a Smartphone and Wearable Detected Arial Arrhythmia in Older Adults Case Finding Study: Smart in OAC - AFNET 9 Front. Cardiovasc. Med., 2022 March 21. doi:10.3389/fcvm.2022.839202

Haeusler KG, Eichner F. A.; Heuschmann P. U.; Fiebach J. B. Engelhorn T, Blank B, Callans D, Elvan A, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR, Mont L, Cosedis Nielsen J, Piccini JP, Schotten U, Themistoclakis S, Vijgen J, di Biase L, Kirchhof P. MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial.  Circulation. 2022;145:906–915. doi: 10.1161/CIRCULATIONAHA.121.056320.

2021

Metzner A, Suling A, Brandes A,  Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Elvan A, Goette A, Haegeli L, Heidbuchel H, Kautzner J, Kuck KH, Mont L, NG A, Szumowski L, Themistoclakis S, van Gelder I, Vardas P, Wegscheider K, Willems S, Kirchhof P. Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. Europace (2021) 00, 1–13, 02 September 2021. doi:10.1093/europace/euab200

Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Gessler N, Goette A, Haegeli L, Heidbuchel H, Kautzner J, NG A, Schnabel R, Suling A,  Szumowski L, Themistoclakis S, Vardas P, van Gelder I, Wegscheider K, Kirchhof P. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. European Heart Journal, 27 August 2021. doi:10.1093/eurheartj/ehab593

Rillig A, Magnussen C, Ozga AK, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Elvan A, Goette A, Gulizia M, Haegeli L, Heidbuchel H, Kuck KH, NG A, Szumowski L, van Gelder I, Wegscheider K, Kirchhof P. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 2021. Epub 30 July 2021. [published online ahead of print]. doi: 10.1161/CIRCULATIONAHA.121.056323

Näbauer et al. Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET). EP Europace 2021 June 17;euab113.
doi: 10.1093/cvr/cvaa295

2020

Goette A. Pathophysiological consequences of the EAST-AFNET4 trial: AF is not an innocent bystander. Cardiovasc Res. 2020 Dec 1;116(14):e200-e201.
doi: 10.1093/cvr/cvaa295

Engler D, Heidbuchel H, Schnabel RB, for the AFFECT-EU Investigators. Digital, risk-based screening for atrial fibrillation in the European community—the AFFECT-EU project funded by the European Union, Eur Heart J. 2021 Feb 20. doi: 10.1093/eurheartj/ehab05

Ladwig KH, Goette A, Atasoy S, Johar H. Psychological aspects of atrial fibrillation: A systematic narrative review: Impact on incidence, cognition, prognosis, and symptom perception. Curr Cardiol Rep. 2020 Sep 10;22 (11):137. doi: 10.1007/s11886-020-01396-w. PMID: 32910300 Free PMC article. Review. 

Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbüchel H, Hindricks G, Kautzner J, Kuck K-H, Mont L, Ng GA, Rekosz J, Schön N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G, for the EAST–AFNET 4 trial investigators. Early rhythm control therapy in patients with atrial fibrillation. New England Journal of Medicine. Epub 29 Aug 2020. doi: 10.1056/NEJMoa2019422

Vranckx P, Valgimigli M, Eckardt L, Lewalter T, Unikas R, Marin F, Schiele F, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Tijssen J, Goette A. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. Eur Heart J. 2020 Aug 29:ehaa617. Online ahead of print. doi: 10.1093/eurheartj/ehaa617

Zink MD, Chua W, Zeemering S, di Biase L, Antoni BL, David C, Hindricks G, Haeusler KG, Al-Khalidi HR, Piccini JP, Mont L, Nielsen JC, Escobar LA, de Bono J, Van Gelder IC, de Potter T, Scherr D, Themistoclakis S, Todd D, Kirchhof P, Schotten U. Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace. 2020 Jul 28:euaa132. Online ahead of print. doi: 10.1093/europace/euaa132

2019

Bertaglia E, Blank B, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, deGroot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, and Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019; 0, 1–9. doi:10.1093/europace/euz172

Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Long-Term General Registry Investigators. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace. 2019 Mar 24. pii: euz032. (first published online) doi:10.1093/europace/euz032. 

Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, Thomas MR, Kotecha D, Lip GYH, Kirchhof P, Fabritz L. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur Heart J. April 2019.  (first published online Jan 2019) doi:10.1093/eurheartj/ehy815

Chua W, Easter CL, Guasch E, Sitch A, Casadei B, Crijns HJGM, Haase D, Hatem S, Kääb S, Mont L, Schotten U, Sinner MF, Hemming K, Deeks JJ, Kirchhof P and Fabritz L. Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset. BMC Cardiovascular Disorders. 21 May 2019. doi:10.1186/s12872-019-1105-4

Chua W, Easter CL, Guasch E, Sitch A, Casadei B, Haase D, Hatem S, Kaab S, Mont L, Schotten U, Sinner M, Hemming K, Deeks JJ, Kirchhof P, Fabritz L, CATCH ME Consortium. Development of a prognostic model for prevalent atrial fibrillation using individual patient data: Results of CATCH ME (P5662). European Heart Journal, Volume 40, Issue Supplement_1, October 2019. doi:10.1093/eurheartj/ehz746.0605

Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019 Oct 25. pii: ehz732. [Epub ahead of print] doi:10.1093/eurheartj/ehz732

Leute, A. Neue Studie testet Antikoagulation bei AHRE. CardioNews. 31.10.2019, Seite 34. app.cardionews.de/ePaper

Mevius A, Wilke T, Fuchs A, Kloppenburg A, Engel S, Linder R, Breithardt G. Catheter Ablation Versus Antiarrhythmic Medication in Patients with Atrial Fibrillation: a Propensity-Matched Analysis Based on a German Claims Data Set. J Cardio Vasc Med. 2019; 5: 1-12. doi:10.17303/jcvm.2019.5.203

Schnabel R, Haeusler KG, Healey J, Freedman B et al for the AF-SCREEN International Collaboration authors group. Searching for Atrial Fibrillation Post-Stroke: A White Paper of the AF-SCREEN International Collaboration. Circulation. 2019; 140. 1834–50. doi:10.1161/CIRCULATIONAHA.119.040267

Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, 3.9.2019. doi:10.1016/S0140-6736(19)31872-0

Willems S, Meyer C, de Bono J, Brandes A, Eckardt L, Elvan A, van Gelder I, Goette A, Gulizia M, Haegeli L, Heidbuchel H, Haeusler KG, Kautzner J, Mont L, Ng GA, Szumowski L, Themistoclakis S, Wegscheider K, Kirchhof P. Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. European Heart Journal. In press. doi:10.1093/eurheartj/ehz782

 

2018

Reinecke H, Jürgensmeyer S, Engelbertz C, et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open 2018 Sep 10;8:e022690. doi: 10.1136/bmjopen-2018-022690

Haeusler KG, et al. Positionspapier zur Detektion von Vorhofflimmern nach ischämischem Schlaganfall. Akt Neurol 2018 Mar; 45:93-106. doi: 10.1055/s-0043-118476. Epub 2017 Oct 26.

Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, Fetsch T, Van Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR, Massaro T, Mont L, Nielsen JC, Nölker G, Piccini JP, De Potter T, Scherr D, Schotten U, Themistoclakis S, Todd D, Vijgen J, Di Biase L. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018 Aug 21; 00:1-14. doi: 10.1093/eurheartj/ehy176. Epub 2018 Mar 20.

Kotecha D, Chua W W L, Fabritz L, Hendriks J, Casadei B, Schotten U, Vardas P, Heidbuchel H, Dean V, Kirchhof P. European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. EP Europace Feb 2018(first published online Oct 2017). DOI: 10.1093/europace/eux299

Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes A, Calkins H, Casadei B, Castellá M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A, Goette A, Guasch E, Haase D, Hatem S, Haeusler KG, Heidbuchel H, Hendriks J, Hunter C, Kääb S, Kespohl S, Landmesser U, Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison L, Potpara T, Ravens U, Richard-Lordereau I, Rienstra M, Savelieva I, Schnabel R, Sinner MF, Sommer P, Themistoclakis S, Van Gelder IS, Vardas PE, Verma A, Wakili R, Weber E, Werring D, Willems S, Ziegler A, Hindricks G, Kirchhof P. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace. 2018 Mar 1; 20(3):395-407. doi: 10.1093/europace/eux318. Epub 2018 Jan 02.

 

2017

Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, Chlouverakis G, Diener HC, Kirchhof P. Atrial high-rate episodes and stroke prevention. Europace. 2017 Feb 1;19(2):169-179. doi: 10.1093/europace/euw279. Epub 2016 Feb 29.

Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Diemberger I, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Long-Term General Registry Investigators. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018 May 1. doi: 10.1093/europace/eux301. Epub 2017 Sep 14.

Di Biase L, Callans D, Georg Haeusler K, Hindricks G, Al-Khalidi H, Mont L, Cosedis Nielsen J, Piccini JP, Schotten U, Kirchhof P. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace. 2017 Jan;19(1):132-138. doi: 10.1093/europace/euw368. Epub 2016 Oct 14.

Kirchhof P. Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines. Heart. 2017 May. pii: heartjnl-2016-310843. doi: 10.1136/heartjnl-2016-310843. Epub 2017 Jan 11.

Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet Apr 2017. DOI: 10.1016/S0140-6736(17)31072-3

Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.

Kotecha D, Kirchhof P. ESC Apps for Atrial Fibrillation. Eur Heart J. 2017 Sep 14;38(35):2643-2645. doi: 10.1093/eurheartj/ehx445.

Okutucu S, Katircioglu-Öztürk D, Oto E, Güvenir HA, Karaagaoglu E, Oto A, Meinertz T, Goette A. Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: 'exposing the invisible'. Europace. 2017 May 1; 19 (5):741 - 746. pii: euw084. doi: 10.1093/europace/euw084 . Epub 2016 Oct 11.

 

2016

Eckardt L, Häusler KG, Ravens U, Borggrefe M, Kirchhof P. ESC-Leitlinien zum Vorhofflimmern 2016 (ESC guidelines on atrial fibrillation 2016: Summary of the most relevant recommendations and modifications). Herz. 2016 Dec;41(8):677-683.  doi: 10.1007/s00059-016-4503-8. Epub 2016 Nov 15.

Fabritz L, Kirchhof P. Can biomarkers balance stroke and bleeding risk. The Lancet June 2016 (first published online April 2016). DOI: 10.1016/S0140-6736(16)30121-0

Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kääb S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol. April 2016 (first published online 2015 Dec 24). DOI:10.1038/nrcardio2015.194

Ferner M, Wachtlin D, Konrad T, Deuster O, Meinertz T, von Bardeleben S, Münzel T, Seibert-Grafe M, Breithardt G, Rostock T. Rationale and design of the RE-LATED AF-AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus-Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol. 2016; 105:29-36. doi:10.1007/s00392-015-0883-7. Epub 2015 Jun 25.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis A, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal Oct 2016. DOI: 10.1093/eurheartj/ehw210

Kirchhof P, Calkins H. Catheter ablation in patients with persistent atrial fibrillation. European Heart Journal July 2016. DOI: 10.1093/eurheartj/ehw260

Kirchhof P, Goette A, Näbauer M, Schotten U, 12 Jahre AFNET. Vom Forschungsnetzwerk zur Academic Research Organization. Bundesgesundheitsblatt April 2016; 59 (4):514 - 522. doi: https://doi.org/10.1007/s00103-016-2323-x . Epub 2016 Mar 15.

Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt L, Lewalter T, Breithardt G, Willems S; Gap-AF–AFNET 1 Investigators. Impact of complete versus incomplete circumferential lines around the pulmonary veins during catheter ablation of paroxysmal atrial fibrillation: Results from the Gap-AF – AFNET 1 trial. Circ Arrhythm Electrophysiol. 2016 Apr; 4:514 - 522; 9:e003337. doi: 10.1161/CIRCEP.115.003337 . Epub 2016 Jan 13.

Lankveld T, de Vos CB, Limantoro I, Zeemering S, Dudink E, Crijns HJ, Schotten U. Systematic analysis of ECG predictors of sinus rhythm maintenance after electrical cardioversion for persistent atrial fibrillation. Heart Rhythm May 2016.  DOI: 10.1016/j.hrthm.2016.01.004

Lankveld T, Zeemering S, Scherr D, Kuklik P, Hoffmann BA, Willems S, Pieske B, Haïssaguerre M, Jaïs P, Crijns HJ, Schotten U. Atrial Fibrillation Complexity Parameters Derived From Surface ECGs Predict Procedural Outcome and Long-Term Follow-Up of Stepwise Catheter Ablation for Atrial Fibrillation. Circulation:Arrhythmia and Electrophysiology Feb 2016. DOI: 10.1161/CIRCEP.115.003354

Linz D, Hohl M, Dhein S, Ruf S, Reil JC, Kabiri M, Wohlfart P, Verheule S, Böhm M, Sadowski T, Schotten U. Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats. Cardiovascular Research Mar 2016. DOI: 10.1093/cvr/cvw071

Oto E, Okutucu S, Katircioglu-Öztürk D, Altay Güvenir H, Karaagaoglu E, Borggrefe M, Breithardt G, Goette A, Ravens U, Steinbeck G, Wegscheider K, Oto A, Kirchhof P. Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. Europace. 2017 Jun 1; 19 (6):921 - 928. pii: euw144. doi: 10.1093/europace/euw144 . Epub 2016 Jul 2

Sauer W, Callans D. The Tribulations of Atrial Fibrillation Ablation Trialists (Editorial). Circ Arrhythm Electrophysiol. 2016; 9:e003738. doi: 10.1161/CIRCEP.115.003738

Schotten U, Dobrev D, Platonov PG, Kottkamp H, Hindricks G. Current controversies in determining the main mechanisms of atrial fibrillation. Journal of Internal Medicine Mar 2016. DOI: 10.1111/joim.12492

Spronk HMH, De Jong AM, Verheule S, De Boer HC, Maass AH, Lau, M Rienstra DH, van Hunnik A, Kuiper M, Lumeij S, Zeemering S, Linz D, Kamphuisen PW, ten Cate H, Crijns HJ, Van Gelder IC, van Zonneveld AJ, Schotten U. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. European Heart Journal Apr 2016. DOI: 10.1093/eurheartj/ehw119

Weckbach LT, Grabmaier U, Clauss S, Wakili R. MicroRNAs as a diagnostic tool for heart failure and atrial fibrillation. Current Opinion in Pharmacology Feb 2016. DOI: 10.1016/j.coph.2016.01.001

 

2015

Bosch R, Benninger G, Pittrow D, Paar WD, von Stritzky B, Goette A. Effektivität und Verträglichkeit von Dronedaron bei Patienten mit paroxysmalem oder persistierendem Vorhofflimmern unter Praxis-bedingungen: IMPULS -Studie. Abstract P456. Clin. Res. Cardiol. 104, Suppl 1, 2015 Apr 9. doi: 10.1007/s00392-015-1100-4. Epub 2015 Apr 08.

Clauss S, Sinner MF, Kääb S, Wakili R. The Role of MicroRNAs in Antiarrhythmic Therapy for Atrial Fibrillation. Arrhythmia & Electrophysiology Review Dec 2015. DOI: 10.15420/aer.2015.4.3.146

Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kääb S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol. 2016 Apr; 13 (4):230-237 . doi: 10.1038/nrcardio.2015.194. Epub 2015 Dec 24.

Goette A, Benninger G, Pittrow D, Paar WD, von Stritzky B, Bosch RF. One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care. Herzschrittmacherther Elektrophysiol. 2015 Jun; 26:148-54. doi: 10.1007/s00399-015-0360-z. Epub 2015 Mar 8.

Haegeli L, Aliot E, Brandes A, Eckardt L, Elvan A, Gulizia M, Heidbuchel H, Kautzner J, Mont L, Morgan J, Ng A, Szumowski L, Themistoclakis S, Van Gelder IC, Willems S, Kirchhof P. The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. Eur Heart J. 2015 Feb 1;36(5):255-6. doi: 10.1093/eurheartj/ehu476. Epub 2015 Jan 30.

Haeusler KG, Gerth A, Limbourg T, Tebbe U, Oeff M, Wegscheider K, Treszl A, Ravens U, Meinertz T, Kirchhof P, Breithardt G, Steinbeck G, Nabauer M; AFNET registry investigators. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry. BMC Neurol. 2015 Aug 5;15:129. doi: 10.1186/s12883-015-0371-8.

Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S, Ziegler A, Lip GYH, Camm AJ. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 2016 Jan 1; 18 (1):37-50 doi: 10.1093/europace/euv304 . Epub 2015 Oct 18.

Reinecke H, Näbauer M, Gerth A, Limbourg T, Treszl A, Engelbertz C, Eckardt L, Kirchhof P, Wegscheider K, Ravens U, Meinertz T, Steinbeck G, Breithardt G. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int. 2015; 87:200-9. doi: 10.1038/ki.2014.195. Epub 2014 Jun 4.

Von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P, Ladwig KH. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis-data from the German Competence Network on Atrial Fibrillation. Europace. 2015; 17:1354-62. doi: 10.1093/europace/euv018. Epub 2015 Mar 30.

 

2014

Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014 Jan;16(1):6-14. doi: 10.1093/europace/eut263

Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G, Krijthe BP, Chasman DI, Barnard J, Kleber ME, Dörr M, Ozaki K, Smith AV, Müller-Nurasyid M, Walter S, Agarwal SK, Bis JC, Brody JA, Chen LY, Everett BM, Ford I, Franco OH, Harris TB, Hofman A, Kääb S, Mahida S, Kathiresan S, Kubo M, Launer LJ, Macfarlane PW, Magnani JW, McKnight B, McManus DD, Peters A, Psaty BM, Rose LM, Rotter JI, Silbernagel G, Smith JD, Sotoodehnia N, Stott DJ, Taylor KD, Tomaschitz A, Tsunoda T, Uitterlinden AG, Van Wagoner DR, Völker U, Völzke H, Murabito JM, Sinner MF, Gudnason V, Felix SB, März W, Chung M, Albert CM, Stricker BH, Tanaka T, Heckbert SR, Jukema JW, Alonso A, Benjamin EJ, Ellinor PT. Novel Genetic Markers Associate with Atrial Fibrillation Risk in Europeans and Japanese. J Am Coll Cardiol. 2014 Jan 17. pii: S0735-1097(14)00171-5. doi: 10.1016/j.jacc.2013.12.015.

Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S, Bis JC, Lin H, Chung MK, Nielsen JB, Lubitz SA, Krijthe BP, Magnani JW, Ye J, Gollob MH, Tsunoda T, Müller-Nurasyid M, Lichtner P, Peters A, Dolmatova E, Kubo M, Smith JD, Psaty BM, Smith NL, Jukema JW, Chasman DI, Albert CM, Ebana Y, Furukawa T, Macfarlane PW, Harris TB, Darbar D, Dörr M, Holst AG, Svendsen JH, Hofman A, Uitterlinden AG, Gudnason V, Isobe M, Malik R, Dichgans M, Rosand J, Van Wagoner DR; METASTROKE Consortium; AFGen Consortium, Benjamin EJ, Milan DJ, Melander O, Heckbert SR, Ford I, Liu Y, Barnard J, Olesen MS, Stricker BH, Tanaka T, Kääb S, Ellinor PT. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation. 2014 Oct 7;130(15):1225-35. doi: 10.1161/CIRCULATIONAHA.114.009892.

Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XH, Nattel S, Dobrev D. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014 Jan 14;129(2):145-56. doi:10.1161/CIRCULATIONAHA.113.006641.

von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T, Calvert M, Baumert J, Ladwig KH. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enroled in two large clinical trials. Europace. 2014 Jun; 16(6):812-9. doi: 10.1093/europace/eut 361

Wasmer K, Köbe J, Eckardt L. Antiarrhythmic therapy of atrial fibrillation: are we treating too late? Herzschrittmacherther Elektrophysiol. 2014 Aug 21. doi: 10.1007/s00399-014-0331-9

 

2013

Apostolakis S, Haeusler KG, Oeff M, Treszl A, Andresen D, Borggrefe M, Lip GY, Meinertz T, Parade U, Samol A, Steinbeck G, Wegscheider K, Breithardt G, Kirchhof P. Low stroke risk after elective cardioversion of atrial fibrillation: An analysis of the Flec-SL trial. Int J Cardiol. 2013 Jul 17. doi: 10.1016/j.ijcard.2013.06.090

Ahmad Y, Kirchhof P. Gone fishing (for silent atrial fibrillation) (editorial comment). Circulation. 2013;127:870-872. doi: 10.1161/CIRCULATIONAHA.112.000985

Fabritz L, Kirchhof P. Selective atrial profibrotic signalling in mice and man. Cardiovasc Res. 2013 Sep 1;99(4):592-4. doi: 10.1093/cvr/cvt188

Goette A. Upstream therapy for atrial fibrillation in heart failure. Heart Fail Clin. 2013; 9(4):417-25, viii. doi: 10.1016/j.hfc.2013.07.010

Heijman J, Voigt N, Abu-Taha IH, Dobrev D. Rhythm control of atrial fibrillation in heart failure. Heart Fail Clin. 2013; 9(4):407-415.

Heijman J, Heusch G, Dobrev D. Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin Med Insights:Cardiol. 2013; 7:127-140.

Heijman J, Dobrev D. Pleiotropic actions of amiodarone: still puzzling after half a century. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jul;386(7):571-4. doi: 10.1007/s00210-013-0865-0

Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, Bailleul C, Bax J, Benninger G, Blomstrom-Lundqvist C, Boersma L, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Casadei B, Clemens A, Crijns H, Derwand R, Dobrev D, Ezekowitz M, Fetsch T, Gerth A, Gillis A, Gulizia M, Hack G, Haegeli L, Hatem S, Hausler KG, Heidbuchel H, Hernandez-Brichis J, Jais P, Kappenberger L, Kautzner J, Kim S, Kuck K-H, Lane D, Leute A, Lewalter T, Meyer R, Mont L, Moses G, Mueller M, Munzel F, Nabauer M, Nielsen JC, Oeff M, Oto A, Pieske B, Pisters R, Potpara T, Rasmussen L, Ravens U, Reiffel J, Richard-Lordereau I, Schafer H, Schotten U, Stegink W, Stein K, Steinbeck G, Szumowski L, Tavazzi L, Themistoclakis S, Thomitzek K, Van Gelder IC, von Stritzky B, Vincent A, Werring D, Willems S, Lip GYH, Camm AJ. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013; 15:1540-56. doi: 10.1093/europace/eut232

Kirchhof P, Breithardt G, Camm AJ, Crijns H, Kuck K-H, Vardas P, Wegscheider K. Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J 2013; 166(3):442-8. doi:10.1016/j.ahj.2013.05.015

Kirchhof P. [Atrial fibrillation: current recommendations for diagnosis and treatment]. Internist 2013;54(5):583-95.

Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, John Camm A. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J. 2013 May;34(20):1471-4. doi: 10.1093/eurheartj/ehs446

Kirchhof P, Marijon E, Fabritz L, Li N, Wang W, Wang T, Schulte K, Hanstein J, Schulte JS, Vogel M, Mougenot N, Laakmann S, Fortmueller L, Eckstein J, Verheule S, Kaese S, Staab A, Grote-Wessels S, Schotten U, Moubarak G, Wehrens XH, Schmitz W, Hatem S, Müller FU. Overexpression of cAMP-response element modulator causes abnormal growth and development of the atrial myocardium resulting in a substrate for sustained atrial fibrillation in mice. Int J Cardiol. 2013 Jun 20;166(2):366-74.

Lin H, Sinner MF, Brody JA, Arking DE, Lunetta KL, Rienstra M, Lubitz SA, Magnani JW, Sotoodehnia N, McKnight B, McManus DD, Boerwinkle E, Psaty BM, Rotter JI, Bis JC, Gibbs RA, Muzny D, Kovar CL, Morrison AC, Gupta M, Folsom AR, Kääb S, Heckbert SR, Alonso A, Ellinor PT, Benjamin EJ; on behalf of the CHARGE Atrial Fibrillation Working Group. Targeted sequencing in candidate genes for atrial fibrillation: The Cohorts for Heart and Aging Research in Genomic Epidemiology Targeted Sequencing Study. Heart Rhythm. 2013 Nov 14. pii: S1547-5271(13)01316-7. doi: 10.1016/j.hrthm.2013.11.012

Voigt N, Zhou X, Dobrev D. Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents. J Vis Exp. 2013 Jul 3;(77):e50235. doi: 10.3791/50235.

von Eisenhart Rothe AF, Bielitzer M, Meinertz T, Limbourg T, Ladwig KH, Goette A. Predictors of discordance between physicians' and patients' appraisals of health-related quality of life in atrial fibrillation patients: Findings from the Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial. Am Heart J. 2013 Sep;166(3):589-596.e1. doi: 10.1016/j.ahj.2013.05.020.

 

2012

Breithardt G, Ravens U, Kirchhof P, van Gelder I. Vorhofflimmern und Blutungskomplikationen – Atrial fibrillation and bleeding complications. Nervenheilkunde 2012; 31: 791-95

Breithardt G. Volkskrankheit Vorhofflimmern (Editorial). Nervenheilkunde 2012; 31: 783

Camm AJ, Savelieva I: The long and short of antiarrhythmic drug treatment (comment). Lancet 18.06.2012, doi:10.1016/S0140-6736(12)60950-7

Dobrev D. Is Altered Atrial microRNA-ome a Critical Contributor to Pathophysiology of Atrial Fibrillation? Basic Res Cardiol 2012; 107: 284-287

Dobrev D, Carlsson L, Nattel S. Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 2012; 11(4): 275-91

Dobrev D, Singh BN. Antiarrhythmic drugs. In “Electrophysiological Disorders of the Heart”. Eds. Sanjeev Saksena, A John Camm, 2nd edition, 2012; pp. 1133-1157, Elsevier Science, Waltham, MA, USA

Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Müller-Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dörr M, Ozaki K, Roberts JD, Smith JG, Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wagoner DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, Launer LJ, Davies RW, Borkovich M, Harris TB, Lin H, Völker U, Völzke H, Milan DJ, Hofman A, Boerwinkle E, Chen LY, Soliman EZ, Voight BF, Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, Conen D, Tsunoda T, Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, Nakamura Y, Parvez B, Mahida S, Furie KL, Rosand J, Muhammad R, Psaty BM, Meitinger T, Perz S, Wichmann HE, Witteman JC, Kao WH, Kathiresan S, Roden DM, Uitterlinden AG, Rivadeneira F, McKnight B, Sjögren M, Newman AB, Liu Y, Gollob MH, Melander O, Tanaka T, Stricker BH, Felix SB, Alonso A, Darbar D, Barnard J, Chasman DI, Heckbert SR, Benjamin EJ, Gudnason V, Kääb S. Meta-analysis identifies six new susceptibility loci for atrial fibrillation.
Nat Genet 2012; 44(6):670-5. doi: 10.1038/ng.2261

Gerth A, Nabauer M, Limbourg T, Meinertz M, Oeff M, Kirchhof P, Treszl A, Wegscheider K, Breithardt G, Steinbeck G. Versorgungswirklichkeit in Deutschland: AFNET-Register – State of medical care for patients with atrial fibrillation in Germany. Nervenheilkunde 2012; 31: 807-12

Goette A, Hammwöhner M, Bukowska A, Martens-Lobenhoffer J, Dobrev D, Ravens U, Scalera F, Weinert S, Medunjanin S, Braun-Dullaues RC, Lendeckel U, Bode-Böger S. The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol 2012; 154: 141-146

Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial.
Circ Arrhythm Electrophysiol. 2012; 5;43-51. DOI:10.1161/CIRCEP.111.965178

Harada M, Luo X, Qi XY, Tadevosyan A, Maguy A, Ordog B, Ledoux J, Kato T, Naud P, Voigt N, Shi Y, Kamiya K, Murohara T, Kodama I, Tardif JC, Schotten U, Van Wagoner DR, Dobrev D, Nattel S. TRPC3-dependent Fibroblast Regulation in Atrial Fibrillation. Circulation 2012; 126: 2051-2064. (Editorial in Circulation, 2012, 126:2039-2041)

Häusler KG, Tebbe U, Willems S, Sprenger C, Kirchhof P, Endres M, Oeff M. Neurologische Komplikationen nach linksatrialer Katheterablation bei Vorhofflimmern – Neurological complications after left atrial catheter ablation for atrial fibrillation. Nervenheilkunde 2012; 31: 830-35

Heijman J, Dobrev D. Systems approaches to post-operative atrial fibrillation – do they help us to better understand the ionic basis of the arrhythmogenic substrate? J Mol Cell Cardiol 2012; 53: 320-322

Heijman J, Voigt N, Nattel S, Dobrev D. Atrial Ca2+ handling and atrial fibrillation. Wien Med Wochenschr 2012; 162(13-14): 287-291

King A: Is short-term antiarrhythmic therapy an option? Nature Reviews Cardiology 10.07.2012, doi:10.1038/nrcardio.2012.97

Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, Steinbeck G, Treszl A, Wegscheider K, Breithardt G: Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012; 380: 238-246, doi:10.1016/S0140-6736(12)60570-4

Kirchhof P, Gulba D, Hindricks G, Goette A. Leitlinien der Europäischen Gesellschaft für Kardiologie – Guidelines of the ESC – management of atrial fibrillation. Nervenheilkunde 2012; 31: 821-25

Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options – a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2012; 14: 8-27

Kirchhof P, Nitschmann S: Dronedaron bei Hochrisikopatienten mit Vorhofflimmern (PALLAS Studie). Internist 2012; 53: 1248-50. DOI: 10.1007/s00108-012-3145-z

Li N, Wang T, Wang W, Cutler MJ, Wang Q, Voigt N, Rosenbaum DS, Dobrev D, Wehrens XHT. Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knock-out mice. Circ Res 2012; 110(3): 465-70

Meinertz T, Goette A, Kirchhof P, Treszl A, Wegscheider K. Antiarrhythmische Pharmakotherapie – Antiarrhythmic drug therapy after cardioversion. Nervenheilkunde 2012; 31: 826-829

Müssigbrodt A, Eitel C, Hindricks G, Sommer P. EKG Diagnostik von Vorhofflimmern – ECG registration in atrial fibrillation. Nervenheilkunde 2012; 31: 797-805

Nattel S, Dobrev D. The multidimensional role of cellular calcium signaling in atrial fibrillation pathophysiology: Mechanistic insights and therapeutic opportunities. Eur Heart J 2012; 33(15): 1870-1877

Respress JL, Van Oort RJ, Li N, Rolim N, Dixit S, deAlmeida A, Voigt N, Lawrence W, Skapura DS, Scardal K, Wisloff U, Wieland T, Ai X, Pogwizd S, Dobrev D, Wehrens XHT. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res 2012; 110: 1474-1483. (Editorial in Circ Res, 100: 1398-1402)

Rizos T, Güntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R, Hepp T, Kirchhof P, Aleynichenko E, Ringleb P, Hacke W, Veltkamp R: Continuous Stroke Unit Electrocardiographic Monitoring versus 24-Hour Holter Electrocardiography for Detection of Paroxysmal Atrial Fibrillation after Stroke. Stroke 2012; 43:2689-94, doi: 10.1161/STROKEAHA.112.654954

Voigt N, Dobrev D. Cellular and Molecular Correlates of Ectopic Activity in Patients with Atrial Fibrillation. Europace 2012; 14 (Suppl. 5). v97-v105

Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland T, Ravens R, Nattel S, Wehrens XHT, Dobrev D: Enhanced Sarcoplasmic Reticulum Ca2+ Leak and Increased Na+-Ca2+ Exchanger Function Underlie Delayed Afterpolarizations in Patients with Chronic Atrial Fibrillation.
Circulation 2012, 125:2059-70, doi: 10.1161/CIRCULATIONAHA.111.067306

Voigt N, Nattel S, Dobrev D. Proarrhythmic Atrial Calcium Signalling in the Diseased Heart. Adv Exp Med Biol 2012; 740: 1175-1192

Zellerhoff S, Lewalter T, Eckardt L, Treszl A, Wegscheider K, Breithardt G. Antithrombotische Therapie bei nichtvalvulärem Vorhofflimmern – New anticoagulants in patients with non-valvular atrial fibrillation. Nervenheilkunde 2012; 31: 813-20

Zhou XB, Dobrev D. Voltage-gated Na+ channels: novel players in fibroblast-to-myofibroblast transition with a potential role in atrial arrhythmogenesis? J Physiol 2012; 590 (20): 4975

 

2011

Boontje NM, Merkus D, Zaremba R, Versteilen A, de Waard M, Mearini G, de Beer VJ, Carrier L, Walker LA, Niessen HW, Dobrev D, Stienen GJM, Duncker DJ, van der Velden J. Enhanced myofilament responsiveness upon β-adrenergic stimulation in post-infarct remodeled myocardium. J Mol Cell Cardiol 2011, 50(3): 487-99.

Cunha SR, Hund TJ, Hashemi S, Voigt N, Li N, Wright P, Koval O, Li J, Gudmundsson H, Schott JJ, Probst V, Le Marec H, Karck M, Anderson ME, Dobrev D, Wehrens XH, Mohler PJ. Defects in ankyrin-based membrane protein targeting pathways underlie atrial fibrillation. Circulation 2011, 124(11): 1212-1222. (Editorial in Sci Transl Med, 2011 Sept 14, 3(100): 100ec149).

Dobrev D. Prevention of atrial fibrillation complications with antiarrhythmic drugs: a still unmet need in the clinical practice. Expert Opin Pharmacother 2011, 12(8): 1195-1199.

Dobrev D, Nattel S. New insights into the molecular basis of atrial fibrillation: mechanistic and therapeutic implications. Cardiovasc Res 2011, 89(4): 689-691.

Dobrev D, Voigt N, Wehrens X. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res 2011, 89(4): 734-743.

Ehrlich JR, Dobrev D. Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation? Naunyn Schmiedebergs Arch Pharmacol. 2011;384(2):109-14. DOI:10.1007/s00210-011-0647-5.

Gerth A, Nabauer M, Limbourg T, Oeff M, Sprenger C, Ravens U, Meinertz T, Breithardt G, Steinbeck G.Risk factors for thromboembolic events and impact of the CHA2DS2-VASc risk score on risk stratification in atrial fibrillation: Results from the German AFNET Registry. Eur Heart J 2011;32 (Suppl 1):463

Gerth A, Nabauer M, Limbourg T, Oeff M, Sprenger C, Ravens U, Meinertz T, Breithardt G, Steinbeck G. Undertreatment and discontinuation of antithrombotic treatment in the Central Registry of the German Competence NETwork on Atrial Fibrillation (AFNET). Eur Heart J 2011;32 (Suppl 1):46

Grandi E*, Pandit S*, Voigt N*, Workman AJ, Dobrev D, Jalife J, Bers DM. Human Atrial Action Potential and Ca2+ Model: Sinus Rhythm and Chronic Atrial Fibrillation. Circ Res 2011, 109(9): 1055-66. *equally contributed first authors

Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Vardas P, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost. 2011; 106/6: 993-1234. DOI:10.1160/TH11-07-0517

Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A, Wegscheider K, Treszl A, Meinertz T, Oeff M, Ravens U, Breithardt G, Steinbeck G, on behalf of the AFNET registry investigators. Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011; 105: 1010-23. DOI:10.1160/TH11-02-0070

Le Quang K, Naud P, Qi XY, Duval F, Shi YF, Gillis MA, Comtois P, Tardif JC, Li D, Levesque PC, Dobrev D, Charpentier F, Nattel S. Role of T-type calcium current subunits in post myocardial infarction cardiac remodeling probed with genetically engineered knockout mice. Cardiovasc Res 2011, 91(3): 420-428. (Editorial in Cardiovasc Res, 91(3): 373-375).

Makary S*, Voigt N*, Maguy A*, Wakili R, Nishida K, Harada M, Dobrev D, Nattel S. Differential PKC Isoform Regulation and Increased Constitutive Activity of Acetylcholine-regulated Potassium Channels in Atrial Remodeling. Circ Res 2011, 109(9): 1031-43. *equally contributed first authors

Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P; ATRIUM investigators. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 2011;100:897-905. DOI:10.1007/s00392-011-0320-5.

Nishida K, Qi XY, Wakili R, Comtois P, Chartier D, Harada M, Iwasaki YK, Romeo P, Maguy A, Dobrev D, Michael G, Talajic M, Nattel S. Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. Circulation. 2011;123:137-46. DOI:10.1161/CIRCULATIONAHA.110.972778

Richards MA, Clarke JD, Saravanan P, Voigt N, Dobrev D, Eisner DA, Trafford AW, Dibb KM.  Transverse t-tubules are a common feature in large mammalian atrial myocytes including human. Am J Physiol Heart Circ Physiol 2011, 301(5): H1996-2005.

Schnabel RB, Kerr KF, Lubitz SA, Alkylbekova EL, Marcus GM, Sinner MF, Magnani JW, Wolf PA, Deo R, Lloyd-Jones DM, Lunetta KL, Mehra R, Levy D, Fox ER, Arking DE, Mosley TH, Müller-Nurasyid M, Young TR, Wichmann HE, Seshadri S, Farlow DN, Rotter JI, Soliman EZ, Glazer NL, Wilson JG, Breteler MM, Sotoodehnia N, Newton-Cheh C, Kääb S, Ellinor PT, Alonso A, Benjamin EJ, Heckbert SR; Candidate Gene Association Resource (CARe) Atrial Fibrillation / Electrocardiography Working Group. Large-scale candidate gene analysis in whites and African Americans identifies IL6R polymorphism in relation to atrial fibrillation: the National Heart, Lung, and Blood Institute's Candidate Gene Association Resource (CARe) project. Circ Cardiovasc Genet. 2011;4:557-64.
DOI:10.1161/CIRCGENETICS.110.959197

Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325. Review. Erratum in: Physiol Rev. 2011;91:1533. DOI:10.1152/physrev.00031.2009

Sinner MF, Ellinor PT, Meitinger T, Benjamin EJ, Kääb S. Genome-wide association studies of atrial fibrillation: past, present, and future. Cardiovasc Res. 2011;89:701-9. Review. DOI:10.1093/cvr/cvr001.

Sinner MF, Lubitz SA, Pfeufer A, Makino S, Beckmann BM, Lunetta KL, Steinbeck G, Perz S, Rahman R, Sonni A, Greenberg SM, Furie KL, Wichmann HE, Meitinger T, Peters A, Benjamin EJ, Rosand J, Ellinor PT, Kääb S. Lack of replication in polymorphisms reported to be associated with atrial fibrillation.
Heart Rhythm. 2011;8:403-9. DOI:10.1016/j.hrthm.2010.11.003.

Sprenger C, Breithardt G, Haeusler KG, Meinertz T, Ravens U, Steinbeck G, Tebbe U, Oeff M. Causes of death in patients with atrial fibrillation - data from the German Competence Network on Atrial Fibrillation. Europace 2011, 13 ( 3 ), Abstract 862

Swaminathan PD, Purohit A, Soni S, Voigt N, Singh M, Glukhov A, Gao Z, He JB, Luczak ED, Joiner ML, Kutschke W, Yang J, Donahue JK, Weiss RM, Grumbach IM, Ogawa M, Chen PS, Efimov I, Dobrev D, Mohler PJ, Hund TJ, Anderson ME. Oxidized CaMKII causes cardiac sinus node dysfunction in mice. J Clin Invest, 121(8): 3277–3288 (Commentary in J Clin Invest 2011, 121(8): 2975-2977).

Tsuji Y, Hojo M, Voigt N, El-Armouche A, Inden Y, Murohara T, Dobrev D, Nattel S, Kodama I, Kamiya K.  Ca2+-related Signaling and Protein Phosphorylation Abnormalities Play Central Roles in a New Experimental Model of Electrical Storm. Circulation 2011, 123: 2192-2203. (Editorial in Circulation, 123: 2183-2186).

Van Gelder IC, Haegeli LM, Brandes A, Heidbuchel H, Aliot E, Kautzner J, Szumowski L, Mont L, Morgan J, Willems S, Themistoclakis S, Gulizia M, Elvan A, Smit MD, Kirchhof P. Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 2011;13:1517-25. DOI:10.1093/europace/eur192.

Voigt N, Dobrev D. Ion channel remodeling in atrial fibrillation. European Cardiology 2011, 7(2): 97–103.

Wakili R, Voigt N, Kääb S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121:2955-68. DOI:10.1172/JCI46315. Review.

Wittköpper K, Dobrev D, Eschenhagen T, El-Armouche A. Phosphatase-1-inhibitor-1 in physiological and pathological β-adrenoceptor signalling. Cardiovasc Res 2011, 91(3): 392-401.

 

2010

Dobrev D, Wehrens XH. Calmodulin kinase II, sarcoplasmic reticulum Ca2+ leak, and atrial fibrillation. Trends Cardiovasc Med. 2010 Jan;20(1):30-4. Review

Dobrev D, Voigt N, Wehrens XH. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res. 2010 Nov 3. [Epub ahead of print].

Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, de Bakker PI, Mueller M, Lubitz SA, Fox E, Darbar D, Smith NL, Smith JD, Schnabel RB, Soliman EZ, Rice KM, Van Wagoner DR, Beckmann BM, van Noord C, Wang K, Ehret GB, Rotter JI, Hazen SL, Steinbeck G, Smith AV, Launer LJ, Harris TB, Makino S, Nelis M, Milan DJ, Perz S, Esko T, Köttgen A, Moebus S, Newton-Cheh C, Li M, Möhlenkamp S, Wang TJ, Kao WH, Vasan RS, Nöthen MM, MacRae CA, Stricker BH, Hofman A, Uitterlinden AG, Levy D, Boerwinkle E, Metspalu A, Topol EJ, Chakravarti A, Gudnason V, Psaty BM, Roden DM, Meitinger T, Wichmann HE, Witteman JC, Barnard J, Arking DE, Benjamin EJ, Heckbert SR, Kääb S. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet. 2010 Mar;42(3):240-4.

Lendeckel U, Dobrev D, Goette A. Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol. 2010 Apr;159(8):1581-3.

Lubitz SA, Ozcan C, Magnani JW, Kääb S, Benjamin EJ, Ellinor PT. Genetics of  atrial fibrillation: implications for future research directions and personalized medicine. Circ Arrhythm Electrophysiol. 2010 Jun 1;3(3):291-9. Review.

Lubitz SA, Sinner MF, Lunetta KL, Makino S, Pfeufer A, Rahman R, Veltman CE, Barnard J, Bis JC, Danik SP, Sonni A, Shea MA, Del Monte F, Perz S, Müller M, Peters A, Greenberg SM, Furie KL, van Noord C, Boerwinkle E, Stricker BH, Witteman J, Smith JD, Chung MK, Heckbert SR, Benjamin EJ, Rosand J, Arking DE, Alonso A, Kääb S, Ellinor PT. Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation. 2010 Sep 7;122(10):976-84.

Milan DJ, Lubitz SA, Kääb S, Ellinor PT. Genome-wide association studies in cardiac electrophysiology: recent discoveries and implications for clinical practice. Heart Rhythm. 2010 Aug;7(8):1141-8. Review.

Nabauer M, Gerth A, Kirchhof P, Goette A, Limbourg T, Sprenger C, Hoffmann B, Willems S, Doll N, Schuchert A, Oeff M, Ravens U, Meinertz T, Steinbeck G, Breithardt G. [Registry and studies of the German Competence Network on Atrial Fibrillation (AFNET)]. Herzschrittmacherther Elektrophysiol. 2010 Sep;21(3):153-9.

Nishida K, Michael G, Dobrev D, Nattel S. Animal models for atrial fibrillation: clinical insights and scientific opportunities. Europace. 2010 Feb;12(2):160-72.

Pfeufer A, van Noord C, Marciante KD, Arking DE, Larson MG, Smith AV, Tarasov KV, Müller M, Sotoodehnia N, Sinner MF, Verwoert GC, Li M, Kao WH, Köttgen A, Coresh J, Bis JC, Psaty BM, Rice K, Rotter JI, Rivadeneira F, Hofman A, Kors JA, Stricker BH, Uitterlinden AG, van Duijn CM, Beckmann BM, Sauter W, Gieger C, Lubitz SA, Newton-Cheh C, Wang TJ, Magnani JW, Schnabel RB, Chung MK, Barnard J, Smith JD, Van Wagoner DR, Vasan RS, Aspelund T, Eiriksdottir G, Harris TB, Launer LJ, Najjar SS, Lakatta E, Schlessinger D, Uda M, Abecasis GR, Müller-Myhsok B, Ehret GB, Boerwinkle E, Chakravarti A, Soliman EZ, Lunetta KL, Perz S, Wichmann HE, Meitinger T, Levy D, Gudnason V, Ellinor PT, Sanna S, Kääb S, Witteman JC, Alonso A, Benjamin EJ, Heckbert SR. Genome-wide association study of PR interval. Nat Genet. 2010 Feb;42(2):153-9.

Ravens U, Christ T. Atrial-selective drugs for treatment of atrial fibrillation. Herzschrittmacherther Elektrophysiol. 2010 Dec;21(4):217-21.

Ravens U. Antiarrhythmic therapy in atrial fibrillation. Pharmacol Ther. 2010 Oct;128(1):129-45.

Ravens U. Novel pharmacological approaches for antiarrhythmic therapy. Naunyn Schmiedebergs Arch Pharmacol. 2010 Mar;381(3):187-93

Sinner MF, Lubitz SA, Pfeufer A, Makino S, Beckmann BM, Lunetta KL, Steinbeck G, Perz S, Rahman R, Sonni A, Greenberg SM, Furie KL, Wichmann HE, Meitinger T, Peters A, Benjamin EJ, Rosand J, Ellinor PT, Kääb S. Lack of replication in polymorphisms reported to be associated with atrial fibrillation. Heart Rhythm. 2010 Nov 4. [Epub ahead of print]

Voigt N, Trausch A, Knaut M, Matschke K, Varró A, Van Wagoner DR, Nattel S, Ravens U, Dobrev D. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Oct 1;3(5):472-80.

Wakili R, Yeh YH, Yan Qi X, Greiser M, Chartier D, Nishida K, Maguy A, Villeneuve LR, Boknik P, Voigt N, Krysiak J, Kääb S, Ravens U, Linke WA, Stienen GJ, Shi Y, Tardif JC, Schotten U, Dobrev D, Nattel S. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol. 2010; 3:530-41.

 

2009

Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, Smith AV, Schnabel RB, Bis JC, Boerwinkle E, Sinner MF, Dehghan A, Lubitz SA, D'Agostino RB Sr, Lumley T, Ehret GB, Heeringa J, Aspelund T, Newton-Cheh C, Larson MG, Marciante KD, Soliman EZ, Rivadeneira F, Wang TJ, Eiríksdottir G, Levy D, Psaty BM, Li M, Chamberlain AM, Hofman A, Vasan RS, Harris TB, Rotter JI, Kao WH, Agarwal SK, Stricker BH, Wang K, Launer LJ, Smith NL, Chakravarti A, Uitterlinden AG, Wolf PA, Sotoodehnia N, Köttgen A, van Duijn CM, Meitinger T, Mueller M, Perz S, Steinbeck G, Wichmann HE, Lunetta KL, Heckbert SR, Gudnason V, Alonso A, Kääb S, Ellinor PT, Witteman JC. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet. 2009; 41(8):879-81.

Body SC, Collard CD, Shernan SK, Fox AA, Liu KY, Ritchie MD, Perry TE, Muehlschlegel JD, Aranki S, Donahue BS, Pretorius M, Estrada JC, Ellinor PT, Newton-Cheh C, Seidman CE, Seidman JG, Herman DS, Lichtner P, Meitinger T, Pfeufer A, Kääb S, Brown NJ, Roden DM, Darbar D. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ Cardiovasc Genet. 2009 Oct;2(5):499-506

Chelu MG, Sarma S, Sood S, Wang S, van Oort RJ, Skapura DG, Li N, Santonastasi M, Müller FU, Schmitz W, Schotten U, Anderson ME, Valderrábano M, Dobrev D, Wehrens XH. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest. 2009;119(7):1940-51.

Dobrev D. Ion channel portrait of the human sinus node: useful for a better understanding of sinus node function and dysfunction in humans? Circulation, 119(12): 1556-1558, 2009

Dobrev D, Goette A, Ravens U. Stroke prevention versus risk of bleeding of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery. Cardiovasc Ther (formerly Cardiovascular Drug Reviews), 27: 223-225, 2009

Dobrev D, Teos LY, Lederer WJ. Unique atrial myocyte Ca2+ signaling. J Mol Cell Cardiol. 2009; 46(4):448-51.

Gemein C, Schauerte P, Hatam N, Rana OR, Saygili E, Meyer C, Eickholt C, Schmid M, Knackstedt C, Zarse M, Mischke K. Targeting of cardiac autonomic plexus for modulation of intracardiac neural tone. Europace. 2009; 11(8):1090-6.

Gerth A, Nabauer M, Limbourg T, Oeff M, Ravens U, Meinertz T, Breithardt G, Steinbeck G. Gender-specific differences in symptom burden and management of atrial fibrillation in the AFNET: Data from a large prospective clinical registry. Eur Heart J 2009; 30 (Abstract Suppl): 818

Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH, Ehrlich JR. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009; 6(12):1802-9.

Goette A*, Bukowska A*, Dobrev D*, Pfeiffenberger J, Morawietz H, Strugala D, Wiswedel I, Röhl FW, Bergmann S, Bramlage P, Ravens U, Lendeckel U. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J, 05.03.2009; *shared first authorship

Greiser M, Neuberger HR, Harks E, El-Armouche A, Boknik P, de Haan S, Verheyen F, Verheule S, Schmitz W, Ravens U, Nattel S, Allessie MA, Dobrev D, Schotten U. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J Mol Cell Cardiol. 2009; 46(3):385-94.

Hinterseer M, Beckmann BM, Thomsen MB, Pfeufer A, Dalla Pozza R, Loeff M, Netz H, Steinbeck G, Vos MA, Kääb S. Relation of increased short-term variability of QT interval to congenital long-QT syndrome. Am J Cardiol. 2009; 103(9):1244-8.

Kääb S, Darbar D, van Noord C, Dupuis J, Pfeufer A, Newton-Cheh C, Schnabel R, Makino S, Sinner MF, Kannankeril PJ, Beckmann BM, Choudry S, Donahue BS, Heeringa J, Perz S, Lunetta KL, Larson MG, Levy D, MacRae CA, Ruskin JN, Wacker A, Schömig A, Wichmann HE, Steinbeck G, Meitinger T, Uitterlinden AG, Witteman JC, Roden DM, Benjamin EJ, Ellinor PT. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J. 2009; 30(7):813-9.

Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip G, Nattel S, Page R, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive management of AF: Proceedings from the 2nd AFNET-EHRA consensus conference on atrial fibrillation entitled “research perspectives in AF”. Europace 2009; 11(7):860-85.

Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip G, Nattel S, Page R, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive management of AF: Executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference “research perspectives in AF”. Eur Heart J 2009; 30(24):2969-80.

Michael G, Xiao L, Qi XY, Dobrev D, Nattel S. Remodeling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. Cardiovasc Res, 81(3): 491-9. 2009

Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009; 11:423-34.

Nattel S, Burstein B, Dobrev D. Molecular remodeling and chronic atrial fibrillation. In ”Cardiac Electrophysiology: From Cell to Bedside”. Eds. Douglas Zipes, Jose Jalife. 5th edition, Chapter 43, pp 453-465, Saunders, Elsevier, USA. 2009

Pfeufer A, Sanna S, Arking DE, Müller M, Gateva V, Fuchsberger C, Ehret GB, Orrú M, Pattaro C, Köttgen A, Perz S, Usala G, Barbalic M, Li M, Pütz B, Scuteri A, Prineas RJ, Sinner MF, Gieger C, Najjar SS, Kao WH, Mühleisen TW, Dei M, Happle C, Möhlenkamp S, Crisponi L, Erbel R, Jöckel KH, Naitza S, Steinbeck G, Marroni F, Hicks AA, Lakatta E, Müller-Myhsok B, Pramstaller PP, Wichmann HE, Schlessinger D, Boerwinkle E, Meitinger T, Uda M, Coresh J, Kääb S, Abecasis GR, Chakravarti A. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet. 2009; 41(4):407-14.

Saygili E, Rana OR, Meyer C, Gemein C, Andrzejewski MG, Ludwig A, Weber C, Schotten U, Krüttgen A, Weis J, Schwinger RH, Mischke K, Rassaf T, Kelm M, Schauerte P. The angiotensin-calcineurin-NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteinases-2/-9 in atrial myocytes. Basic Res Cardiol. 2009; 104(4):435-48.

Zellerhoff S, Pistulli R, Mönnig G, Hinterseer M, Beckmann BM, Köbe J, Steinbeck G, Kääb S, Haverkamp W, Fabritz L, Gradaus R, Breithardt G, Schulze-Bahr E, Böcker D, Kirchhof P. Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J Cardiovasc Electrophysiol. 2009; 20(4):401-7.

 

2008

Andrié R, Goette A, Lewalter T. Verhinderung von Vorhofflimmern: Rhythmuskontrolle. Klinikarzt 2008; 37 (2): 73-79

Breithardt G, Dobrev D, Doll N, Goette A, Hoffmann B, Kirchhof P, Köster I, Kuck KH, Leute A, Meinertz T, Näbauer M, Oeff M, Ravens U, Schuchert A, Sprenger C, Steinbeck G, Willems S. The German Competence Network on Atrial Fibrillation (AFNET). Herz. 2008 Dec;33(8):548-555.

Breithardt G. Vorhofflimmern – wenn das Herz aus dem Takt gerät. Klinikarzt 2008; 37 (2): 64

Bukowska A, Lendeckel U, Krohn A, Keilhoff G, ten Have S, Neumann KH, Goette A. Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney. Europace. 2008 Oct;10(10):1212-7. Epub 2008 Aug 8.

Bukowska A, Schild L, Keilhoff G, Hirte D, Neumann M, Gardemann A, Neumann KH, Röhl FW, Huth C, Goette A, Lendeckel U. Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia. Exp Biol Med (Maywood). 2008 May;233(5):558-74.

Christ T, Wettwer E, Voigt N, Hála O, Radicke S, Matschke K, Várro A, Dobrev D, Ravens U. Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol. 2008 Aug;154(8):1619-30.

Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol. 2008 Oct;52(4):293-9.

Dobrev D, Teos LY, Lederer WJ. Unique atrial myocyte Ca(2+) signaling. J Mol Cell Cardiol. 2009;46:448-451. 

Dobrev D, Wettwer E. Four and a half LIM protein 1: a novel chaperone for atrium-specific Kv1.5 channels with a potential role in atrial arrhythmogenesis. Cardiovasc Res. 2008 Jun 1;78(3):411-2.

Dobrev D. New concepts in understanding and modulating atrial repolarisation in patients with atrial fibrillation. J Interv Card Electrophysiol. 2008 Aug;22(2):107-10. Epub 2008 Mar 11. Review.

Doll N, Suwalski P, Aupperle H, Walther T, Borger M, Schoon H-A, Mohr FW. Endocardial laser ablation fort the treatment of atrial fibrillation in an acute sheep model. Journal of Cardiac Surgery 2008;23:198-203.

Drewitz I, Rostock T, Hoffmann B, Steven D, Servatius H, Meinertz T, Willems S. Aktuelle Therapiestrategien bei Vorhofflimmern; unter Mitarbeit des Kompetenznetzes Vorhofflimmern (AFNET). [In Process Citation] Med Klin (Munich). 2008 Nov 15;103(11):788-800.

Eckstein J, Verheule S, de Groot N, Allessie M, Schotten U. Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. Prog Biophys Mol Biol. 2008 Jun-Jul;97(2-3):435-51. Review.

El-Armouche A, Wittköpper K, Degenhardt F, Weinberger F, Didié M, Melnychenko I, Grimm M, Peeck M, Zimmermann WH, Unsöld B, Hasenfuss G, Dobrev D, Eschenhagen T.  Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res. 2008;80(3):396-406.

Goette A, Braun-Dullaeus RC. Atrial fibrillation is associated with impaired cognitive function and hippocampal atrophy: silent cerebral ischaemia vs. Alzheimer's disease? Eur Heart J. 2008;29:2067-2069

Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwöhner M, Strugala D, Pfeiffenberger J, Röhl FW, Huth C, Ebert MP, Klein HU, Röcken C. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation. 2008;117(6):732-42.

Goette A, D'Alessandro A, Bukowska A, Kropf S, Mewis C, Stellbrink C, Tebbenjohanns J, Weiss C, Lendeckel U.  Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation. Clin Drug Investig. 2008;28(9):565-72.

Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace. 2008;10(2):238-41. Review.

Greiser M, Neuberger HR, Harks E, El-Armouche A, Boknik P, de Haan S, Verheyen F, Verheule S, Schmitz W, Ravens U, Nattel S, Allessie MA, Dobrev D, Schotten U. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J Mol Cell Cardiol. 2008;46:385-394

Kirchhof P, Breithardt G. Vorhofflimmern – eine Standortbestimmung: Vorkommen, Mechanismen und klinische Präsentation. Klinikarzt 2008; 37 (2): 66-70

Kirchhof P; Fortmueller L, Waldeyer C, Breithardt G, Fabritz L: Drugs that interact with cardiac electro-mechanics: Old and new targets for treatment; Progr Biophys Mol Biol 2008;97:497-512

Knackstedt C, Gramley F, Schimpf T, Mischke K, Zarse M, Plisiene J, Schmid M, Lorenzen J, Frechen D, Neef P, Hanrath P, Kelm M, Schauerte P.  Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation. Cardiovasc Pathol. 2008 Sep-Oct;17(5):318-24.

Knackstedt C, Schauerte P, Kirchhof P. Electro-anatomic mapping systems in arrhythmias. Europace. 2008 Nov;10 Suppl 3:iii28-34.

Knecht S, Oelschläger C, Duning T, Lohmann H, Albers J, Stehling C, Heindel W, Breithardt G, Berger K, Ringelstein EB, Kirchhof P, Wersching H. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29:2125-2132

Knecht S, Wersching H, Lohmann H, Bruchmann M, Duning T, Dziewas R, Berger K, Ringelstein EB. High-normal blood pressure is associated with poor cognitive performance. Hypertension. 2008;51(3):663-8.

Koebe J, Kirchhof P. Novel non-pharmacological approaches for antiarrhythmic therapy of atrial fibrillation. Europace. 2008;10(4):433-7. Review.

Leute A, Breithardt G. Volkskrankheit Vorhofflimmern. Forum Sanitas 2008; 3: 3-5

Leute A, Doll N, Goette A, Kääb S, Kirchhof P, Kuck KH, Meinertz T, Näbauer M, Oeff M, Ravens U, Schuchert A, Steinbeck G, Willems S, Weiß T, Breithardt G. Klinische Studien und Register im Kompetenznetz Vorhofflimmern. DZKF 2008; 12: 71-78

Lutomsky B, Willems S, Meinertz T. Prävention von Schlaganfällen bei Vorhofflimmern: Antithrombotische Therapie. Klinikarzt 2008; 37 (2): 89-94

Meinertz T, Willems S. Treatment of atrial fibrillation in every days practice. Internist (Berl). 2008 Dec;49(12):1437-42, 1444-5.

Nattel S, Burstein B, Dobrev D. Atrial remodelling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol. 2008; 1: 62-73.

Plisiene J, Blumberg A, Haager G, Knackstedt C, Latsch J, Norra C, Arndt M, Tuerk S, Heussen N, Kelm M, Predel HG, Schauerte P. Moderate physical exercise: a simplified approach for ventricular rate control in older patients with atrial fibrillation. Clin Res Cardiol. 2008;97(11):820-6.

Qi XY, Yeh YH, Xiao L, Burstein B, Maguy A, Chartier D, Villeneuve LR, Brundel BJJM, Dobrev D, Nattel N. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res. 2008; 103(8): 845-854.

Schauerte P, Näbauer M, Steinbeck G. Einstellung der Kammerfrequenz bei persistierendem und permanentem Vorhofflimmern: Frequenzkontrolle. Klinikarzt 2008; 37 (2): 81-86

Schuchert A, Wegscheider K, Meinertz T. Stellenwert präventiver Vorhofstimulation zur Reduktion von paroxysmalem Vorhofflimmern bei Schrittmacherpatienten (BACEPACE-Studie). Effect of preventive atrial pacing on the reduction of paroxysmal atrial fibrillation in pacemaker patients (BACEPACE study). Kardiologe 2008; 2(6): 500-505

Sinner MF, Pfeufer A, Akyol M, Beckmann BM, Hinterseer M, Wacker A, Perz S, Sauter W, Illig T, Näbauer M, Schmitt C, Wichmann HE, Schömig A, Steinbeck G, Meitinger T, Kääb S. The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur Heart J. 2008;29(7):907-14.

Sood S, Chelu M, Van Oort R, Skapura D, Santonastasi M, Dobrev D, Wehrens XHT. Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. Heart Rhythm 2008; 5(7): 1047-54.

Sprenger C, Oeff M, Tebbe U, Breithardt G, Meinertz T, Ravens U, Steinbeck G, Häusler KG. Zerebrovaskuläre Komplikationen bei Vorhofflimmern - Zwischenanalyse des prospektiven Registers des Kompetenznetz Vorhofflimmern. Clin Res Cardiol Suppl. 2008; 97: V337

Voigt N, Maguy A, Yeh YH, Qi X, Ravens U, Dobrev D, Nattel S. Changes in IK,ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovasc Res. 2008; 77: 35-43.

Yeh Y-H, Wakili R, Qi X, Chartier D, Boknik P, Kääb S, Ravens U, Coutu P, Dobrev D, Nattel S. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythmia Electrophysiol. 2008; 1: 93-102.

 

2007

Breithardt G, Leute A: The German Competence Network on Atrial Fibrillation – From Basic Research to Patient Care; Hjerteforum (Journal of the Norwegian Cardiac Society), Jun. 2007

Breithardt G: Editorial „Das Kompetenznetz Vorhofflimmern schreitet fort – aktuelle Berichte“; Die Medizinische Welt, April 2007

Cosio F, Aliot E, Botto G, Heidbüchel H, Geller J, Kirchhof P, J-C DH, Frank R, Villacastin J, Vijgen J, Crijns H: Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences - reasons for change to active antiarrhythmic treatment at the time of the first detected episode; Europace 2007;10:21-27

Dobrev D, Christ T, Boknik P, Wöhrl S, Bosch RF, Ravens U: Regulation of left atrial L-type Ca2+ channels in patients with chronic atrial fibrillation; J Mol Cell Cardiol, 42 (Suppl. 1): S20 (doi:10.1016/j.yjmcc.2007.03.057)

Dobrev D: 5-Hydroxytryptamine and atrial arrhythmogenesis: a “culprit mechanism” or a bystander in patients with chronic atrial fibrillation, J Mol Cell Cardiol 2007, 42: 51-3

Doll N, Czesla M, Borger M, Merk D, Mohr FW; Die chirurgische Behandlung des Vorhofflimmerns- Surgical treatment of atrial fibrillation; Die Medizinische Welt, April 2007

Drewitz I, Ernst S, Kuck K-H, Breithardt G, Lutomsky B, Willems S: Katheterablation von Vorhofflimmern – Pulmonary vein ablation – the GAP-AF trial“ : Die Medizinische Welt, April 2007

El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S, Dobrev D, Eschenhagen T, Carrier L: Decreased phosphorylation levels of cardiac myosin binding protein-C in human and experimental heart failure; J Mol Cell Cardiol 2007; 43:223-229

Fabritz L, Breithardt G, Kirchhof P.: Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models; Cardiovasc Hematol Agents Med Chem. 2007; 5(4):289-294

Goette A, Breithardt G, Fetsch T, Hanrath P, Klein HK, Lehmacher 5, Steinbeck G, Meinertz T.: Angiotensin II-Antagonist inParoxysmal Atrial Fibrillation (ANTIPAF)-Trial: rationale and study design; Clin Drug Invest 2007; 27(10):697-705

Goette A, Bukowska A, Lendeckel U: Non-ionchannel blockers as antiarrhythmic drugs (reversal of structural remodelling): Curr Opin Pharmacol 2007;7:219-224

Goette A, D’Alessandro A, Meinertz T: Die ANTIPAF Studie. Aktivierung des Renin-Angiotensin-Systems - ein neuer Faktor für das Entstehen von Vorhofflimmern?; Med Welt 2007; 58:138-140

Goette A, Lendeckel U, Klein HU.: Elektrophysiologie und Pathophysiologie von Vorhofflimmern.; In: Vorhofflimmern Vorhofflattern (Neuzner J & Pitschner HF, Eds.). pp 39-73, Steinkopff Verlag Darmstadt, 2007

Goette A, Lendeckel U, Kuchenbecker A, Bukowska A, Peters B, Klein H, Huth C, Röcken C.: Cigarette smoking induces via nicotine a proarrhythmic atrial fibrosis in humans., Heart. 2007;93(9):1056-63.

Greiser M, Halaszovich CR, Frechen D, Boknik P, Ravens U, Dobrev D, Lückhoff A, Schotten U: Pharmacological evidence for altered src-kinase regulation of ICa,L in patients with chronic atrial fibrillation., Naunyn Schmiedeberg’s Arch Pharmacol, 2007 375(6):383-92.

Hammwöhner M, D'Alessandro A, Wolfram O, Goette A: New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation; Curr Vasc Pharmacol. 2007;5(3):211-9.

Hammwöhner M, Ittenson A, Dierkes J, Bukowska A, Lendeckel U, Klein H, Goette A:, Increased expression of CD40/CD40L and adhesion molecules during AF, Exp Biol Med 2007;232(4):581-589.

Hammwöhner M, Ittenson A, Dierkes J, Bukowska A, Peters B, Klein H, Lendeckel U, Goette A.: Platelet Expression of CD40/CD40 Ligand And its Relation to Inflammatory Markers and Adhesion Molecules in Patients with Atrial Fibrillation., Exp Biol Med, 2007, 232(4):581-9.

Kääb S, Schotten U, Dobrev D, Kirchhof P, Ravens U, Götte A: Grundlagenforschung ist eine Voraussetzung für innovative pharmakologische Therapieansätze bei Vorhofflimmern.; MedWelt 2007; 58: 131-134.

Kirchhof P, Andresen D,. Meinertz T,. Steinbeck G,. Weiss T,. Breithardt G; „Gezielte pharmakologische Umkehr des elektrischen Remodelling durch Kurzzeit-Antiarrhythmika-Therapie? – Targeted phermacological reversal of electrical remodelling by short-term antiarrhythmic drug treatment after cardioversion. The Flec-SL study within AFNET“ ; Die Medizinische Welt, April 2007

Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al: Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace. 2007;9:1006-1023.

Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G:  Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007;28:2803-2817.

Kirchhof P, Breithardt G:  Behandlung von Vorhofflimmern, Internist (Berl). 2007 Aug;48:819-31.

Kirchhof P, Breithardt G: New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation.; Heart Rhythm 2007;4 (6): 790-3

Kirchhof P, Goette A, Hindricks G, Hohnloser S, Kuck KH, Meinertz T, Ravens U, Steinbeck G, Breithardt G. Endpunkte für Studien bei Patienten mit Vorhofflimmern - Bericht über ein Konsensus-Papier von AFNET und EHRA. Herzschrittmachertherapie & Elektrophysiologie volume 18, pages259–268(2007). 

Kirchhof P, Klimas J, Fabritz L, Zwiener M, Jones LR, Schafers M, et al.: Stress and high heart rate provoke ventricular tachycardia in mice expressing triadin.; J Mol Cell Cardiol. 2007;42:962-71.

Kirchhof P: New antiarrhythmic drugs and new concepts for old drugs.; Journal of Interventional Cardiac Electrophysiologie 2007

Leute A: AFNET/EHRA Consensus Conference on Endpoints for Atrial Fibrillation Trials”; EHRA Newsletter 3/2007

Näbauer M: Viele Alte mit hohem Risiko sind nicht antikoaguliert; Cardio News 2007; 06:10, 29

Roell W, Lewalter T, Sasse P, Tallin Y, Choi BR, Breitbach M, Doran R, Becher U, Hwang S-M, Bostani T, von Maltzahn J, Hofmann A, Reining S, Doering B, Gabris B, Pfeifer A, Welz A, Willecke K, Salama G, Schrickel J, Kotlikoff M, Fleischmann B: Engraftment of connexin43-expressing cells prevents post-infarct arrythmia; Nature 2007;450:819-824

Schotten U, de Haan S, Verheule S, Harks E, Frechen D, Bodewig E, Greiser M, Ram R, Maessen J, Kelm M, Allessie M, Van Wagoner D.: Blockade of atrial-specific K-currents increases atrial but not ventricular contractility by enhancing reverse mode Na/Ca-exchange., Cardiovasc Res 2007;73:37-47

Schrickel JW, Brixius K, Herr C, Clemen C, Sasse P, Reetz K, Grohé C, Meyer R, Tiemann K, Schröder R, Bloch W, Nickening G, Fleischmann B, Noegel A, Schwinger R, Lewalter T: Enhanced heterogeneity of myocardial conduction and severe cardiac electrical instability in annexin A7-deficient mice, Cardiovasc Res 2007; 257-268

Voigt N, Friedrich A, Bock M, Wettwer E, Christ T, Knaut M, Strasser RH, Ravens U, Dobrev D: Differential phosphorylation-dependent regulation of constitutively active and muscarinic-receptor activated IK,ACh channels in patients with chronic atrial fibrillation, Cardiovasc Res. 2007 74(3):426-37

Voigt N, Maguy A, Yeh YH, Qi X, Ravens U, Dobrev D, Nattel S.: Changes in lK, ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes; Cardiovasc Res. 2007;77:35-43.

Wetter E, Christ T, Dobrev D, Ravens U: Novel antiarrhythmic agents for treatment of atrial fibrillation, Curr Opin Pharmacol 2007, 7(2): 214-218

 

2006

Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, West K, Kashuk C, Akyol M, Perz S, Jalilzadeh S, Illig T, Gieger C, Guo CY, Larson MG, Wichmann HE, Marban E, O'donnell CJ, Hirschhorn JN, Kääb S, Spooner PM, Meitinger T, Chakravarti A.: A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization; Nat Genet. 2006;38(6):644-651

Aupperle and Doll N. Reply to the Editor: Histological findings induced by different energy sources in experimental atrial ablation in sheep. J Thorac Cardiovasc Surg.2006; 132: 213-214.

Barth AS, Kääb S: MAPK= mitogen-activated protein KChIP2? Unraveling signaling pathways controlling cardiac Ito expression.; Circ Res. 2006; 98(3):301-2

Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, Zwermann L, Kaab S, Kreuzer E, Steinbeck G, Mansmann U, Poustka A, Nabauer M, Sultmann H: Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies; J Am Coll Cardiol. 2006;48(8):1610-7. Epub 2006 Sep 27.

Bukowska A, Lendeckel U, Hirte D, Wolke C, Striggow F, Röhnert P, Huth C,. Klein HU, Goette A.  (2006) Activation of the Calcineurin Signaling Pathway Induces Atrial Hypertrophy During Atrial Fibrillation. J Cell Mol Life Sci; 63: 333-342.

Dagres N, Kottkamp H, Piorkowski C, Doll N, Mohr F, Horlitz M, Kremastinos DT, Hindricks G: Rapid detection and successful treatment of esophageal perforation after radiofrequency ablation of atrial fibrillation: lessons from five cases. J Cardiovasc Electro-physiol. 2006;17(11):1213-5.

de Haan S, Greiser M, Harks E, Blaauw Y, van Hunnik A, Verheule S, Allessie M, Schotten U: AVE0118, Blocker of the Transient Outward Current (Ito) and Ultrarapid Delayed Rectifier Current (IKur), Fully Restores Atrial Contractility After Cardioversion of Atrial Fibrillation in the Goat. Circulation 2006;114:1234-42

Dobrev D, Ravens U: Do genetics help to better understand the underlying mechanisms of atrial fibrillation? Eur Heart J 2006; 27(14): 1640-1641

Dobrev D: Electrical remodeling in atrial fibrillation.; Herz Cardiovascular Diseases 2006, 31(2): 108-112

Doll N, Mohr FW: Vorhofflimmern: chirurgische Verfahren; In Broschüre Herzrhythmusstörungen heute. Deutsche Herzstiftung Juli 2006.

El-Armouche A, Bednorz A, Pamminger T, Ditz D, Didie M, Dobrev D, Eschenhagen T: Role of calcineurin and protein phosphatase-2A in regulation of phosphatase inhibitor-1 in cardiac myocytes.; Biochem Biophys Res Commun 2006; 346(3): 700-6

El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U, Dobrev D; Molecular determinants of altered Ca2+-handling in human chronic atrial fibrillation.; Circulation 2006; 114; 670-680

Goette A: Innovative therapeutic approach to atrial fibrillation: AT1-receptor blocker.; Dtsch Med Wochenschr. 2006;131 (34-35 Suppl 4): S103-107.

Goette A, Lendeckel U. Morphologisches Remodeling bei Vorhofflimmern. Herz. 2006; 31: 101-107.

Goette A, Schotten U. Inhibition of angiotensin II type 1 receptors reduces atrial stunning and spontaneous echo contrast after electrical cardioversion of atrial fibrillation. Eur Heart J. 2006; 27(17): 2034-2035.

Hammwöhner M, D`Alessandro A, Dobrev D, Kirchhof P, Goette A: Neue Antiarrhythmika in der Therapie des Vorhofflimmerns II. Nicht-Ionenkanalblocker. Herzschr Elektrophys 2006, 17: 73-80. 

Hinterseer M, Becker A, Kääb S, Lang N, Näbauer M, Steinbeck G. Thalidomide-induced symptomatic third-degree atrioventricular block. Clin Res Cardiol. 2006; 95:1-3

Hinterseer M, Irlbeck M, Ney L, Beckmann BM, Pfeufer A, Steinbeck G, Kääb S. Acute respiratory distress syndrome with transiently impaired left ventricular function and Torsades de Pointes arrhythmia unmasking congenital long QT syndrome in a 25-yr-old woman.     Br J Anaesth. 2006; 97(2):150-153

Kääb S: Tuning the Beat: Differential Expression of Ion Channels in the Sinus Node: Circ. Res. 2006; 99; 1283-1284

Kirchhof P, Schotten U.: Hypertension begets hypertrophy begets atrial fibrillation? Insights from yet another sheep model.; Eur Heart J. 2006;27:2919-20.

Knackstedt C, Franke A, Mischke K, Zarse M, Gramley F, Schimpf T, Plisiene J, Muehlenbruch G, Spuentrup E, Ernst S, Willems S, Kirchhof P, Schauerte P.; Semi- automated 3-dimensional intracardiac echocardiography: Development and initial clinical experience of a new system to guide ablation procedures.; Heart Rhythm. 2006;3:1453-9

Leute A, Kirchhof P, Breithardt G, Goette A, Lewalter T, Meinertz T, Oeff M, Ravens U, Steinbeck G, Weiss T.  [German Competence Network on Atrial Fibrillation (AFNET): A nationwide cooperation for better research and patient care; Med Klin 2006; 15;101(8):662-6.

Ravens U, Dobrev D, Götte A: Neue Aspekte in der Therapie des Vorhofflimmerns.; Herzschr Elektrophys 2006; 17: 61-63

Ravens U, Wettwer E, Schotten U, Weßel R, Dobrev D: Neue Antiahythmika in der Therapie des Vorhofflimmerns II. Ionenkanalblocker; Herzschr Elektrophys 2006, 17: 64-72.

Schild L, Bukowska A, Gardemann A, Polczyk P, Täger M, Keilhoff G, Dudley SC, Klein HU, Goette A, Lendeckel U. Rapid pacing of embryoid bodies impairs mitochondrial ATP synthesis by a calcium-dependent mechanism--a model of in vitro differentiated cardiomyocytes to study molecular effects of tachycardia. Biochim Biophys Acta-Mol Basis Dis; 1762(6): 608-15.

Schotten U, Dobrev D, Kirchhof P, Kääb S, Lewalter T, Goette A: Pathophysiologie des Vorhofflimmerns; Deutsches Ärzteblatt. 2006; 103 (25):B1491-B1497.

Schotten U, Dobrev D, Kirchhof P, Kääb S, Lewalter T, Goette A: Vorhofflimmern: Grundlagenforschung bietet neue Chancen für innovative pharmakologische Therapieansätze.; Deutsches Ärzteblatt 2006, 103(25): A1743-A1748. (Joint activity of several Section C network members)

Schotten U, Dobrev D, Kirchhof P, Kääb S, Lewalter T,Goette A: Optimising the management of atrial fibrillation – insights from a national expert network.; Deutsches Ärzteblatt 2006;103:A1743-1748

Suwalski P, Suwalski G, Doll N, Majstrak F, Kurowski A, Suwalski KB: Epicardial beating heart "off-pump" ablation of atrial fibrillation in non-mitral valve patients using new irrigated bipolar radiofrequency technology.; Ann Thorac Surg. 2006;82(5):1876-9. PMID: 17062264 [PubMed - indexed for MEDLINE

Zellerhoff S, Goette A, Kirchhof P: Antikoagulation bei Vorhofflimmern.; Herzschr Elektrophys. 2006; 17: 89-94

 

2005

Barth AS, Merk S, Arnoldi E, Zwermann L, Kloos P, Gebauer M, Steinmeyer K, Bleich M, Kääb S, Pfeufer A, Überfuhr P, Dugas M, Steinbeck G, Näbauer M: Functional profiling of human atrial and ventricular gene expression: Pflugers Arch-Eur J Physiol. 2005; 450: 201-8

Breithardt G: "Das Kompetenznetz Vorhofflimmern"; Medizinische Welt, Sep. 2005

Duning T, Kloska S, Steinsträter O, Kugel H, Heindel W, Knecht S: Dehydration confounds the assessment of brain atrophy; NEUROLOGY 2005; 64: 548-50

Ellinghaus P, Scheubel RJ, Dobrev D, Ravens U, Holtz J, Huetter J, Nielsch U, Morawietz H: Comparing the Global mRNA Expression Profile of Human Atrial and Ventricular Myocardium with High-Density Oligonucleotide Arrays; J Thorac Cardiovasc Surg 2005; 129: 1383-90

Gaborit N, Steenman M, Lamirault G, Le Meur N, Le Bouter S, Lande G, Léger J, Charpentier F, Christ T, Dobrev D, Escande D, Nattel S, Demolombe S: Human Atrial Ion Channel and Transporter Subunit Gene-Expression Remodeling Associated With Valvular Heart Disease and Atrial Fibrillation; Circulation 2005; 112: 471-81

Goette A, Oeff M: Pathophysiologie des Vorhofflimmerns: Therapie der Grundkrankheit; Med Welt 2005; 56: 366-9

Goette A: Aktivierung des Renin-Angiotensin-Systems: Ein neuer Faktor für das Entstehen oder Aufrechterhaltung des Vorhofflimmerns? Die ANTIPAF Studie; Cardio News 3, 2005 ; Seite 49

Goette A: Neue Strategien zur Behandlung von Vorhofflimmern: Beispiel für die gezielte Überprüfung basiswissenschaftlicher Resultate in klinischen Studien.; Newsletter of the BMBF: June 2005

Kääb S, Schulze-Bahr E: Susceptibility genes and modifiers for cardiac arrhythmias; Cardiovascular Research 2005; 67: 397-413

Kirchhof P, Engelen M, Franz MR, Ribbing M, Wasmer K, Breithardt G, Haverkamp W, Eckardt L: Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation; Basic Res Cardiol 2005; 100: 12-20

Kirchhof P, Fabritz L, Franz MR: Recording monophasic action potentials. In: Dhein S, Mohr FW, Delmar M, editors.; Methods in Cardiovascular Research, New York: Futura; 2005. p. 417-31

Kirchhof P, Fetsch T, Hanrath, P, Meinertz T, Steinbeck G, Lehmacher W, Breithardt G: Targeted Pharmacological Reversal of Electrical Remodeling after Cardioversion - Rationale and Design of the Flec-SL Trial; Am Heart J 2005; 150:899.e1-e6

Kirchhof P, Mönnig G, Wasmer K, Heinecke A, Breithardt G, Eckardt L, Böcker D: A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA); Eur Heart J. 2005;26(13):1292-7.

Kirchhof P: Cardiovert! - or better wait a little? First systematic evidence that the initial hours of atrial fibrillation are a "special time"; Heart Rhythm. 2005;2(12):1330-1.

Lendeckel U, Müller C, Röcken C, Laube B, Täger M, Huth C, Klein HU, Goette A: Expression of opioid receptor subtypes and their ligands in fibrillating human atria; PACE 2005; 28 (Suppl.1) S1-S5

Lewalter T, Doll N, Ernst S, Kuck KH, Lutomsky B, Lüderitz B, Mohr FW, Schuchert A, Willems S: Nicht-medikamentöse Therapie des Vorhofflimmerns; Med Welt 2005; 56: 378-85

Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Lévy S, Crijns HJGM: Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euro Heart Survey on Atrial Fibrillation; Eur Heart J. 2005;26:2422-2434.

Pfeufer A, Jalilzadeh S, Perz S, Mueller JC, Hinterseer M, Illig T, Akyol M, Huth C, Schopfer-Wendels A, Kuch B, Steinbeck G, Holle R, Näbauer M, Wichmann HE, Meitinger T, Kääb S: Common Variants in Myocardial Ion Channel Genes Modify the QT-Interval in the General Population. Results From the KORA Study; Circ Res. 2005; 96: 693-701

Schauerte P, Kirchhof P: Medikamentöse Therapie von Vorhofflimmern; Med Welt 2005; 56: 370-5

Vest JA, Wehrens XHT, Reiken SR, Lehnart SE, Dobrev D, Chandra P,  Danilo P, Ravens U, Rosen MR, Marks AR: Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation: Circulation 2005; 111: 2025-32

 

2004

Bukowska A, Lendeckel U, Kähne T, Goette A: Proteomics in myocardial diseases; Pathology Research and Practice 2004; 200: 135-45

Christ T, Boknik P, Wöhrl S, Wettwer E, Graf EM, Bosch RF, Knaut M, Schmitz W, Ravens U, Dobrev D: L-type Ca2+ Current Downregulation in Chronic Human Atrial Fibrillation Is Associated with Increased Activity of Protein Phosphatases; Circulation 2004; 110: 2651-7

Christ T, Rauwolf T, Braun M, Dobrev D, Ravens U, Strasser RH: Recording atrial monophasic action potentials using standard leads: an alternative way to study electrophysiological properties of the human atrium in vivo?; PACE 2004; 27: 1632-7

Christ T, Rauwolf T, Braun M, Dobrev D, Ravens U, Strasser RH. Recording atrial monophasic action potentials using pacemaker leads: a feasible way to study electrophysiological properties of the human atrium in vivo? J Mol Cell Cardiol 2004; 36: Abstract 26

Christ T, Wettwer E, Knaut M, Ravens U, Dobrev D. Chronisches Vorhofflimmern des Menschen ist mit einer Störung der phosphorylierungsabhängigen Regulation des atrialen L-Typ Ca2+-Stroms assoziiert. Z Kardiol 2004; 93: III-91, V285

Dobrev D, Christ T, Ravens U: Muscarinic subtype-2 receptor autoantibodies: actors or bystanders in human atrial fibrillation?; European Heart Journal 2004; 25: 1091-2

Dobrev D: Molekulare Grundlagen des Remodeling bei Vorhofflimmern; Dtsch Med Wochenschr 2004; 129; 827-30

Dobrev D, Christ T, Wettwer E, Boknik P, Schmitz W, Knaut M, Ravens U. Phosphorylation-dependent regulation of L-type calcium currents is impaired during human chronic atrial fibrillation. Circulation 110 (Suppl.): III-129 (Abstract 611)

Dobrev D, Christ T, Wöhrl S, Boknik P, El-Armouche A, Wettwer E, Graf EM, Bosch RF, Schmitz W, Eschenhagen T, Knaut M, Ravens U. Der erniedrigte L-Typ Ca2+-Strom bei chronischem Vorhofflimmern des Menschen ist mit erhöhter Aktivität von Proteinphosphatasen assoziiert. Z Kardiol 2004; 93: III-22, V74

Dobrev D, Christ T, Wöhrl S, Boknik P, Wettwer E, Bosch RF, Schmitz W, Knaut M, Ravens U. Reduced L-type Ca2+ channel current density in chronic human atrial fibrillation is associated with increased PP2A protein phosphatase activity. Heart Rhythm 2004; 1: S123, P386

Dobrev D, Christ T, Wöhrl S, Boknik P, Wettwer E, Graf EM, Bosch RF, Schmitz W, Knaut M, Ravens U. Reduced L-type Ca2+ channel current density in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Naunyn Schmiedeberg’s Arch Pharmacol 2004; 369 (Suppl 1): R58

Dobrev D, Friedrich A, Christ T, Wettwer E, Knaut M, Ravens U. The G-protein gated potassium current IK,ACh is constitutively active in chronic human atrial fibrillation. Heart Rhythm 2004; 1: S220, P69

El-Armouche A, Boknik P, Schmitz W, Ravens U, Eschenhagen T, Dobrev D. Contractile dysfunction in human chronic atrial fibrillation is associated with hyperphosphorylation of phospholamban and phosphatase inhibitor-1. Circulation 2004; 110 (Suppl.): III-15 (Abstract 64)

El-Armouche A, Dobrev D, Boknik P, Schmitz W, Ravens U, Eschenhagen T. Antithetic regulation of phosphatase inhibitor-1 in two common cardiac diseases: Congestive heart failure and chronic atrial fibrillation. Naunyn Schmiedeberg’s Arch Pharmacol 2004; 369 (Suppl 1): R89

Goette A, Lendeckel U: Nonchannel drug targets in atrial fibrillation; Pharmacology and Therapeutics 2004; 102: 17-36

Goette A, Lendeckel U: Tachycardia-induced remodeling: atria and ventricles take a different route; Cardiovascular Research 2004; 63: 194-5

Goette A, Lendeckel U, Klein HU. Molekularbiologie der Herzvorhöfe: Neue Erkenntnisse zur Pathophysiologie des Vorhofflimmerns sowie klinische Implikationen. Z Kardiol 2004; 93: 864-77

Goette A, Röcken C: Atrial amyloidosis and atrial fibrillation: a gender-dependent "arrhythmogenic substrate"?; European Heart Journal 2004; 25, 1185-1186

Goette A, Weber M, Lendeckel U, Welte T, Lutze G, Klein HU: Effect of physical exercise on platelet activity and the von-Willebrand-factor in patients with persistent lone atrial fibrillation; Journal of Interventional Cardiac Electrophysiology 2004; 10: 139-146

Goette A: Die ANTIPAF Studie; Newsletter of the German Network of Competence in Atrial Fibrillation: No 3 . November 2004

Hala O, Wettwer E, Christ T, Dobrev D, Varro A, Knaut M, Ravens U- Antiarrhythmic potential of the IKur block in human atrium as revealed by computer simulation. Pflügers Arch 2004; 447 (Suppl. 1): S65

Hala O, Wettwer E, Christ T, Dobrev D, Varro A, Knaut M, Ravens U. Antiarrhythmic potential of IKur block as revealed by the effects of 4-AP and AVE0118 in human atrial myocardium in comparison with computer simulations. J Mol Cell Cardiol 2004; 36: Abstract 52

Janko S, Hoffmann E, Schimmel S, Matis T, Fetsch T, Wichmann E., Kääb S, Näbauer M, Steinbeck G. Prävalenz von Vorhofflimmern in der Allgemeinbevölkerung: das KORA-AF-EVENT Projekt. Z Kardiol 2004, 93, Suppl. 3; P783

Janko S, Matis T, Fetsch T, Wichmann E, Näbauer M, Kääb S, Steinbeck G, Hoffmann E. Prevalence of atrial fibrillation among the general population: The KORA-AF project. Eur Heart J 2004; 25; P1608

Knecht S, Berger K: Einfluss vaskulärer Faktoren auf die Entwicklung einer Demenz; Deutsches Ärzteblatt 2004; 101: 31–32:A2185-2189

Rauwolf T, Christ T, Braun M, Schnabel A, Dobrev D, Ravens U, Strasser RH. Atriale monophasische Aktionspotentiale - Untersuchung elektrophysiologischer Charakteristika in vivo mittels Standardschrittmacherelektroden. Z Kardiol 2004; 93: III-306, P1058

Wettwer E, Hála O, Christ C, Heubach JF, Dobrev D, Knaut M, Varró A, Ravens U: Role of IKur in Controlling Action Potential Shape and Contractility in the Human Atrium - Influence of Chronic Atrial Fibrillation; Circulation 2004; 110: 2299-2306

 

2003

Goette A, Lendeckel U: New insights into molecular mechanisms of atrial fibrillation: Are we approaching possible novel pharmacological principals for treating this disorder?; Heart Drug 2003; 3(4): 180-190

Goette A., Jentsch-Ullrich K, Lendeckel U, Röcken C, Agbaria M, Auricchio A, Mohren M, Franke A, Klein, HU: Effect of Atrial Fibrillation on Hematopoietic Progenitor Cells. A novel pathophysiological role of the atrial natriuretic peptide?; Circulation 2003; 108: 2446-9

Kirchhof P, Eckardt L, Franz MR, Mönnig G, Loh P, Wedekind H, Schulze-Bahr Breithardt G, Haverkamp W: Prolonged Atrial Action Potential Durations and Polymorphic Atrial Tachyarrhythmias in Patients with Long QT Syndrome; J Cardiovasc Electrophysiol 2003; 14: 1027-33

Kirchhof P, Schulze-Bahr E: Atrial fibrillation, thromboembolism, and haemostasis: causal or casual associations?; Thromb Haemost 2003; 90: 973-5 (editorial comment)